Vial

JUNE 24, 2024

Contract research organizations (CROs) and pharmaceutical companies can leverage these cutting-edge technologies to streamline clinical trials and introduce automation in drug discovery. As clinical trials grow in complexity, the volume of data being gathered and utilized for these studies is expanding.

Clinical Trials 52

Clinical Trials Trials Clinical Research Treatment 52

H1 Blog

DECEMBER 18, 2023

How will AI impact clinical trials? Every year, we take a look at annual predictions to help life sciences, pharmaceutical, and healthcare companies understand larger industry trends and dynamics to prepare for the new year. Will FDA legislation improve diversity? What platforms will key opinion leaders adopt?

Trials 64

Trials Clinical Trials FDA Pharmaceutical Companies 64

H1 Blog

SEPTEMBER 26, 2023

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. When time is of the essence, like in a global pandemic, how do you scale trials internationally for success? Additionally, clinical trials are no longer confined to one country or region.

Trials 59

Trials Clinical Trials International Regulations 59

H1 Blog

JULY 30, 2024

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

JUNE 8, 2023

Trusted Advisors for Scientific Exchange As pharmaceuticals strive to create medications that are more effective and accessible, it’s essential that they engage HCPs early in order to understand the needs of their target audiences.

Drug Development 52

Drug Development Science Pharmaceutical Companies Production 52

Agency IQ

DECEMBER 1, 2023

Comment periods for EMA documents (such as concept, reflection, and guidance papers) generally stay open for at least six months, though these timelines can vary drastically. policy, such as public registers, drafts, reflection papers, concept papers, and guidance documents expected into Q1 2024.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

Agency IQ

MAY 31, 2024

.: Hands-on training course Webinar/Seminar ( OPEN ) EMA 6/03/2024 6/03/2024 EUCOPE’s Life Science Lectures – Episode Five (Joint Clinical Assessments) Webinar/Seminar ( OPEN ) EUCOPE 6/04/2024 6/04/2024 EUDAMED, the pathway to compliance Webinar/Seminar ( OPEN ) Team Person Responsible for Regulatory Compliance (TEAM-PPRC) 6/04/2024 6/04/2024 News (..)

Regulations 40

Regulations Production Compliance Pharmaceuticals 40